Nom du produit:FMOC-ALPHA-METHYL-DL-LEUCINE

IUPAC Name:(2S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-2,4-dimethylpentanoic acid

CAS:678992-19-3
Formule moléculaire:C22H25NO4
Pureté:95%+
Numéro de catalogue:CM596748
Poids moléculaire:367.45

Unité d'emballage Stock disponible Prix($) Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:678992-19-3
Formule moléculaire:C22H25NO4
Point de fusion:-
Code SMILES:CC(C)C[C@](C)(NC(=O)OCC1C2=CC=CC=C2C2=C1C=CC=C2)C(O)=O
Densité:
Numéro de catalogue:CM596748
Poids moléculaire:367.45
Point d'ébullition:
N° Mdl:MFCD02682477
Stockage:

Category Infos

Fluorenes
Fluorene is a polycyclic aromatic hydrocarbon insoluble in water and soluble in many organic solvents. Fluorenes are one of the most important fluorescent molecules with applications in polymers, electronic devices, sensors, and photochromic materials.

Column Infos

LX9211
Diabetes Care, a peer-reviewed journal of the American Diabetes Association publishes the data from Lexicon’s RELIEF-DPN 1 phase 2 study of LX9211. Adaptor-Associated Kinase 1 (AAK1) is linked to clathrin-mediated endocytosis, and plays a critical role in neuropathic pain and various neurological disorders.
Lexicon’s LX9211 is a selective small molecule inhibitor of AAK1, that is developed as a novel non-opioid approach to neuropathic pain. LX9211 is designed to become an efficacious treatment for moderate-to-severe pain due to diabetic peripheral neuropathic pain (DPNP), which is difficult to manage with current approved medications.
LX9211 is in late-stage development, and the patient enrollment of Phase 2b study will be completed by 2024. Its top-line data is expected in Q2 2025. Lexicon received Fast Track Designation from the FDA for LX9211 in DPNP in 2020.

Related Products